|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Macular Dystrophy, Corneal | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Corneal Dystrophies, Hereditary | |||||
| 3 | More general conditions related to this trial | ||||
| Corneal Diseases | |||||
| Eye Diseases | |||||
| Eye Diseases, Hereditary | |||||
| Genetic Diseases, Inborn | |||||
| 4 | Interventions listed in this trial | ||||
| 4-Methylpyrazole | |||||
| saline | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Fomepizole | |||||
| 6 | More general drug interventions related to this trial | ||||
| Antidotes | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Protective Agents | |||||
| 7 | Sponsors listed in this trial | ||||
| University of Utah | |||||